Research programme: long noncoding RNA modulators- Haya Therapeutics
Latest Information Update: 26 Jul 2024
At a glance
- Originator HAYA Therapeutics
- Class Antifibrotics; Hepatoprotectants; Urologics
- Mechanism of Action Long noncoding RNA inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Idiopathic pulmonary fibrosis; Kidney disorders; Liver disorders; Pancreatic disorders; SARS-CoV-2 acute respiratory disease
Most Recent Events
- 10 Jul 2024 Early research in Idiopathic pulmonary fibrosis in Switzerland (unspecified route) (Haya Therapeutics pipeline, July 2024)
- 10 Jul 2024 Early research in Kidney disorders in Switzerland (Parenteral) (Haya Therapeutics pipeline, July 2024)
- 10 Jul 2024 Early research in Liver disorders in Switzerland (Parenteral) (Haya Therapeutics pipeline, July 2024)